3-carbomethoxy-7-hydroxycoumarin | 86788-50-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-carbomethoxy-7-hydroxycoumarin
• 英文别名: 7-benzyloxyl-2-oxo-2H-1-benzopyran-3-carboxylic acid methyl ester；methyl 2-oxo-7-phenylmethoxychromene-3-carboxylate
• CAS: 86788-50-3
• 化学式: C₁₈H₁₄O₅
• 分子量: 310.306
• InChiKey: RBWNINGVXZDJGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-carbomethoxy-7-hydroxycoumarin 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 6.0h， 以82%的产率得到7-(benzyloxy)-2-oxo-2H-chromene-3-carboxylic acid
  参考文献：
  名称：

  N 肽与羟基香豆素和肉桂酸衍生物连接：合成和荧光光谱，抗氧化剂和抗菌性能†

  摘要：

  以盐的形式合成了三肽Tyr–Gly–Ser和一系列与香豆素，肉桂酸和没食子酸的结合物，并研究了它们的抗氧化和抗菌活性。所述Ñ -connecting羟基香豆素，肉桂和没食子酸衍生物的肽和使用的BBr的3报道作为用于肽去甲基化试剂。基于共轭部分结构研究了它们的活性。对其活性的研究表明，共轭三肽7,8-二羟基香豆素肽（17），咖啡酸肽（22）和没食子酸肽（28）在抗氧化活性方面优于抗坏血酸，并且12，14与阿莫西林相比，，24和25表现出最大的抗菌活性。此外，与其他合成化合物相比，水和DMSO中17的令人难以置信的荧光强度和亮度使该肽成为人体中合适的探针。

  DOI：

  10.1039/c8nj00383a
• 作为产物：
  描述：

  7-羟基香豆素-3-羧酸 在 氯化亚砜 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 3-carbomethoxy-7-hydroxycoumarin
  参考文献：
  名称：

  N 肽与羟基香豆素和肉桂酸衍生物连接：合成和荧光光谱，抗氧化剂和抗菌性能†

  摘要：

  以盐的形式合成了三肽Tyr–Gly–Ser和一系列与香豆素，肉桂酸和没食子酸的结合物，并研究了它们的抗氧化和抗菌活性。所述Ñ -connecting羟基香豆素，肉桂和没食子酸衍生物的肽和使用的BBr的3报道作为用于肽去甲基化试剂。基于共轭部分结构研究了它们的活性。对其活性的研究表明，共轭三肽7,8-二羟基香豆素肽（17），咖啡酸肽（22）和没食子酸肽（28）在抗氧化活性方面优于抗坏血酸，并且12，14与阿莫西林相比，，24和25表现出最大的抗菌活性。此外，与其他合成化合物相比，水和DMSO中17的令人难以置信的荧光强度和亮度使该肽成为人体中合适的探针。

  DOI：

  10.1039/c8nj00383a

文献信息

• Benzopyran compounds, process for preparing the same and their use
  申请人：Yang Yushe

  公开号：US20060178405A1

  公开（公告）日：2006-08-10

  The invention relates to the benzopyran compounds of formula (I), or the salts thereof, in which, the bond between 3 and 4 positions is a single or double bond; R 1 represents a hydrogen atom or a C 1-6 alkyl that can be substituted; R 2 represents a hydrogen atom, a C 1-6 alkyl that can be substituted or an aromatic carbocyclic or aromatic heterocyclic group that can be substituted. The invention also relates to a process for preparing such compounds or their salts as well as the use of such compounds or their salts in the preparation of the medicine against type II diabetes mellitus.

  本发明涉及式（I）的苯并吡喃化合物或其盐，其中3和4位置之间的键为单键或双键；R1表示氢原子或可被取代的C1-6烷基；R2表示氢原子，可被取代的C1-6烷基或可被取代的芳香环烷基或芳香杂环基。本发明还涉及制备这种化合物或其盐的方法，以及使用这种化合物或其盐制备针对II型糖尿病的药物。
• BENZOPYRAN COMPOUNDS, PROCESS FOR PREPARING THE SAME AND THEIR USE
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：EP1598345A1

  公开（公告）日：2005-11-23

  The invention relates to the benzopyran compounds of formula (I), or the salts thereof, in which, the bond between 3 and 4 positions is a single or double bond; R1 represents a hydrogen atom or a C1-6 alkyl that can be substituted; R2 represents a hydrogen atom, a C1-6 alkyl that can be substituted or an aromatic carbocyclic or aromatic heterocyclic group that can be substituted. The invention also relates to a process for preparing such compounds or their salts as well as the use of such compounds or their salts in the preparation of the medicine against type II diabetes mellitus.

  本发明涉及式（I）的苯并吡喃化合物或其盐，其中，3-4位之间的键为单键或双键；R1代表氢原子或可被取代的C1-6烷基；R2代表氢原子、可被取代的C1-6烷基或可被取代的芳香碳环或芳香杂环基团。本发明还涉及制备此类化合物或其盐的工艺，以及此类化合物或其盐在制备 II 型糖尿病药物中的用途。
• Cytochrome P450 monooxygenase variants
  申请人：B.R.A.I.N. Biotechnology Research And Information Network AG

  公开号：EP2426198A1

  公开（公告）日：2012-03-07

  The present invention relates to a nucleic acid molecule encoding a polypeptide having cytochrome P450 monooxygenase activity, wherein said polypeptide comprises a reductase domain that deviates by at least one mutation from (a) the reductase domain of cytochrome P450 BM3, wherein the reductase domain of cytochrome P450 BM3 is represented by SEQ ID NO:1; or (b) a reductase domain having at least 95% sequence identity to SEQ ID NO: 1; and wherein said mutation(s) result(s) in an increased cytochrome P450 monooxygenase activity as compared to a polypeptide comprising the reductase domain of SEQ ID NO: 1. The present invention also relates to a vector comprising the nucleic acid molecule of the invention and a host transformed with the vector. Furthermore, the invention relates to a method of producing a polypeptide comprising culturing the host of the invention as well as to a polypeptide encoded by the nucleic acid molecule of the invention or produced by the method of the invention. The present invention further relates to the use of the polypeptide of the invention in biotransformation or fine chemical synthesis, to an oligo- or polynucleotide which specifically hybridizes to the nucleic acid molecule of the invention as well as to a composition and to a kit.

  本发明涉及一种编码具有细胞色素 P450 单加氧酶活性的多肽的核酸分子，其中所述多肽包括一个还原酶结构域，该还原酶结构域通过至少一个突变偏离(a) 细胞色素 P450 BM3 的还原酶结构域，其中细胞色素 P450 BM3 的还原酶结构域由 SEQ ID NO：1表示；或(b)与SEQ ID NO: 1具有至少95%序列同一性的还原酶结构域；并且与包含SEQ ID NO: 1还原酶结构域的多肽相比，所述突变导致细胞色素P450单加氧酶活性增加。本发明还涉及一种包含本发明核酸分子的载体和用该载体转化的宿主。此外，本发明还涉及一种生产多肽的方法，包括培养本发明的宿主以及由本发明的核酸分子编码或由本发明的方法生产的多肽。本发明还涉及本发明多肽在生物转化或精细化学合成中的用途，涉及与本发明核酸分子特异性杂交的寡核苷酸或多核苷酸，还涉及一种组合物和一种试剂盒。
• EP1598345
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells
  作者：Nihed Draoui、Olivier Schicke、Antony Fernandes、Xavier Drozak、Fady Nahra、Amélie Dumont、Jonathan Douxfils、Emmanuel Hermans、Jean-Michel Dogné、Romu Corbau、Arnaud Marchand、Patrick Chaltin、Pierre Sonveaux、Olivier Feron、Olivier Riant

  DOI：10.1016/j.bmc.2013.09.010

  日期：2013.11

  Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression. In this study, we have developed and implemented a stepwise in vitro screening procedure on human cancer cells to identify new potent MCT inhibitors. Various 7-substituted carboxycoumarins and quinolinone derivatives were synthesized and pharmacologically evaluated. Most active compounds were obtained using a palladium-catalyzed Buchwald-Hartwig type coupling reaction, which proved to be a quick and efficient method to obtain aminocarboxycoumarin derivatives. Inhibition of lactate flux revealed that the most active compound 19 (IC50 11 nM) was three log orders more active than the CHC reference compound. Comparison with warfarin, a conventional anticoagulant coumarin, further showed that compound 19 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux. (C) 2013 Elsevier Ltd. All rights reserved.